Product Overview

ZyHMG 75iu Injection is a sterile, lyophilized formulation of human menopausal gonadotropin (HMG) produced by Zydus Lifesciences. The active ingredient, Menotrophin, consists of a mixture of follicle‑stimulating hormone (FSH) and luteinizing hormone (LH) extracted from the urine of post‑menopausal women. Each vial delivers exactly 75 international units of recombinant HMG, designed for subcutaneous or intramuscular administration after reconstitution with the accompanying diluent. The product is supplied in pack sizes of 12, 3, or 6 injections, allowing clinicians to tailor treatment length to individual patient protocols. ZyHMG is indicated for ovulatory dysfunction in women seeking pregnancy and for hormonal support in men with hypogonadotropic hypogonadism or infertility related to deficient gonadotropin secretion.

What is ZyHMG 75iu Injection

ZyHMG belongs to the class of gonadotropin medications used to stimulate the ovaries in assisted reproductive technologies or to restore endogenous gonadotropin production in men. The medication contains a standardized preparation of Menotrophin, which supplies both FSH and LH activity in a physiologic ratio. Unlike single‑hormone preparations, HMG provides a broader hormonal stimulus that can promote follicular development in women and testosterone synthesis in men when endogenous secretion is insufficient. The 75iu strength is commonly employed in clinical protocols that require moderate ovarian stimulation, such as controlled ovarian hyperstimulation (COH) for in‑vitro fertilization (IVF) or ovulation induction. ZyHMG is manufactured under strict Good Manufacturing Practice (GMP) conditions and complies with regulatory standards set by the FDA and the European Medicines Agency (EMA).

Uses and Benefits

The primary clinical use of ZyHMG 75iu Injection is to enhance ovarian response in women undergoing controlled ovarian hyperstimulation for assisted reproduction. By providing exogenous FSH and LH, the drug promotes the development of multiple mature follicles, increasing the chances of successful fertilization and embryo implantation. In male patients, ZyHMG can stimulate Leydig cells to produce testosterone, thereby improving sperm count and quality in cases of hypogonadotropic hypogonadism. Additional benefits include improved menstrual cycle regularity in women with polycystic ovary syndrome (PCOS) who are attempting conception, and the ability to synchronize follicular growth for embryo transfer procedures. Clinical studies have demonstrated higher live‑birth rates when HMG is combined with appropriate adjunctive medications, making it a valuable component of evidence‑based fertility treatment protocols.

How It Works

ZyHMG exerts its pharmacologic effect through sequential activation of the gonadal axis. After subcutaneous injection, the recombinant HMG molecules bind to pituitary gonadotropin receptors, mimicking the natural action of endogenous FSH and LH. In ovarian tissue, FSH stimulates granulosa cell proliferation and aromatase activity, leading to estrogen production and follicular growth, while LH triggers theca cell androgen synthesis and ultimately induces ovulation when adequate follicular maturity is reached. In male patients, the LH component stimulates Leydig cells to increase testosterone secretion, which in turn supports spermatogenesis in the seminiferous tubules. The dual‑hormone composition allows for a more physiologic stimulation pattern compared with FSH‑only preparations, potentially improving treatment outcomes and reducing the required dose. Pharmacokinetic studies indicate that peak plasma concentrations are achieved within hours, and the drug is cleared primarily through metabolic degradation without significant accumulation. The underlying physiology is documented by the National Institutes of Health.

Dosage and Administration

ZyHMG 75iu is administered by subcutaneous or intramuscular injection after reconstitution with the sterile diluent provided by the manufacturer. The standard adult dosing regimen for female infertility typically begins with 75 IU daily for 7 to 12 days, adjusted based on ovarian response as measured by ultrasound and serum estradiol levels. If fewer than three follicles reach the desired size, the dose may be increased incrementally, but should not exceed 150 IU per day without medical supervision. In male hypogonadism, the recommended dose is generally 75 IU administered every other day for a minimum of three months, with periodic testosterone monitoring to guide therapy continuation. Patients should be instructed to rotate injection sites to minimize local irritation and to avoid injecting into areas with visible bruising or skin lesions. Proper storage at 2‑8°C is required until reconstitution, after which the solution must be used within 24 hours.

Side Effects

Like all hormonal medications, ZyHMG may cause adverse reactions, although most are mild and transient. Common side effects include injection site pain or redness, headache, abdominal bloating, and mild nausea. Some patients experience ovarian hyperstimulation syndrome (OHSS), characterized by rapid weight gain, abdominal distension, and shortness of breath; in such cases, treatment should be paused and supportive care provided. Rare but serious complications can involve thromboembolic events, especially in women with pre‑existing risk factors, and allergic reactions ranging from rash to anaphylaxis. Men may report acne, increased libido, or temporary suppression of endogenous hormone production. Patients are advised to report any unexpected symptoms to their healthcare provider promptly, particularly signs of severe abdominal pain, chest pain, or visual disturbances, which may indicate a medical emergency.

Warnings and Precautions

ZyHMG should only be prescribed after a thorough clinical evaluation and baseline hormonal assessment. It is contraindicated in individuals with known hypersensitivity to any component of the formulation, active pelvic infections, or unexplained abnormal uterine bleeding. Women who are pregnant or breastfeeding must avoid its use, as the hormonal stimulation could affect fetal development. Prior to initiation, clinicians should screen for thrombotic risk factors, such as a history of deep‑vein thrombosis or pulmonary embolism, and adjust therapy accordingly. Concomitant use of other gonadotropins or exogenous steroids may alter efficacy and should be coordinated with a qualified physician. Laboratory monitoring of estradiol, testosterone, and gonadotropin levels is recommended at regular intervals to ensure appropriate dosing and to detect any emerging hyperstimulation. Finally, patients should be counseled about the possibility of multiple pregnancy, which is more common with ovarian stimulation protocols that employ HMG. For full prescribing details, see the FDA prescribing information.

Frequently Asked Questions

Question: What condition does ZyHMG 75iu treat? Answer: ZyHMG is indicated for female infertility caused by ovulatory dysfunction and for male hypogonadism or infertility resulting from deficient gonadotropin secretion. It provides the necessary FSH and LH activity to stimulate ovarian follicular development or testicular testosterone production, respectively, supporting conception efforts under medical supervision.

Question: How should ZyHMG be administered? Answer: After reconstitution with the supplied diluent, ZyHMG is injected subcutaneously or intramuscularly. The injection site should be rotated to reduce irritation, and the solution must be used within 24 hours of preparation. Dosage schedules are individualized by the prescribing clinician based on patient response and laboratory monitoring.

Question: What is the typical dosing regimen for ZyHMG? Answer: In women, the usual starting dose is 75 IU administered daily for 7 to 12 days, with dose adjustments guided by ultrasound and serum estradiol levels. For men, the standard protocol involves 75 IU every other day for a minimum of three months, with periodic testosterone testing to assess therapeutic adequacy.

Question: Are there any serious side effects associated with ZyHMG? Answer: Although most adverse events are mild, ZyHMG can cause ovarian hyperstimulation syndrome (OHSS), characterized by rapid weight gain and abdominal pain, as well as rare thromboembolic events and hypersensitivity reactions. Patients should seek immediate medical attention if they experience severe abdominal discomfort, shortness of breath, chest pain, or signs of an allergic reaction.

Question: Can ZyHMG be used during pregnancy? Answer: No, ZyHMG is contraindicated in pregnant or breastfeeding women because exogenous gonadotropin stimulation may affect fetal development. If pregnancy is confirmed, treatment should be discontinued immediately, and a healthcare professional should evaluate next steps. Contraception is recommended for women of childbearing potential throughout the treatment course.

Related Products

• Iladac 10 Mg (Ilaprazole)
• Ilaprazole 10 Mg (Generic)
• Dexona 4mg Injection (Dexamethasone)
• Dexamethasone 4mg Injection (Generic)
• Oxemia 100 Mg
• Oxemia 50mg
• Obnyx 40 mg Capsule (Enzalutamide)
• Doxolin 200mg (Doxofylline)
• Doxofylline 200mg (Generic)
• Bistide 3 mg (Plecanatide)
• Imeglyn 1000 Mg (Imeglimin)
• Imeglyn 500 Mg (Imeglimin)